CORCEPT THERAPEUTICS INC
For the period ended Jun 30, 2026. Filed Jul 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 29, 2026
CORT$75.03+3.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 6. EXHIBITS
| ExhibitNumber | Description of Document |
| 3.1 | Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on May 24, 2023). |
| 3.2 | Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on December 11, 2023). |
| 10.1# | Corcept Therapeutics Incorporated 2024 Incentive Award Plan (as Amended) (incorporated by reference to Appendix A to the registrant's Definitive Proxy Statement on Schedule 14A filed on April 17, 2026). |
| 31.1 | Rule 13a-14(a)/15d-14(a) Certifications of Joseph K. Belanoff, M.D., Chief Executive Officer of the registrant. |
| 31.2 | Rule 13a-14(a)/15d-14(a) Certifications of Atabak Mokari, Chief Financial Officer of the registrant. |
| 32.1 | 18 U.S.C. Section 1350 Certifications of Joseph K. Belanoff, M.D., Chief Executive Officer of the registrant. |
| 32.2 | 18 U.S.C. Section 1350 Certifications of Atabak Mokari, Chief Financial Officer of the registrant. |
| 101 | The following materials from the registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, formatted in Extensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at June 30, 2026 and December 31, 2025, (ii) Unaudited Condensed Consolidated Statements of Income for the three and six month periods ended June 30, 2026 and 2025, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Income for the three and six month periods ended June 30, 2026 and 2025, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the six month periods ended June 30, 2026 and 2025, (v) Unaudited Condensed Consolidated Statements of Stockholders’ Equity and (vi) Notes to Unaudited Condensed Consolidated Financial Statements. |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |
| # | Indicates a management contract or compensatory plan or arrangement. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.